Financialsexperimental
Hyperfine, Inc. (HYPR). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.
USD in thousands
| Cash Flow | FY FY25 31 Dec 2025 | FY FY24 31 Dec 2024 | FY FY23 31 Dec 2023 | FY FY22 31 Dec 2022 | FY FY21 31 Dec 2021 |
|---|---|---|---|---|---|
| Net loss | -35,574 | -40,720 | -44,238 | -73,164 | -64,851 |
| Depreciation | 1,015 | 726 | |||
| Depreciation | 1,090 | 1,009 | 1,054 | ||
| Stock-based compensation expense | 2,801 | 4,362 | 4,741 | 10,652 | 6,901 |
| Write-down of inventory | 75 | ||||
| Write-off of equipment | 121 | 215 | 224 | ||
| Write-off of other assets - related party | 984 | ||||
| Payments received on net investment in lease | 10 | ||||
| Change in fair value of warrant liabilities | -825 | ||||
| Other | 27 | -11 | 25 | 91 | |
| Accounts receivable, net | 702 | -2,767 | -1,086 | -1,550 | -379 |
| Unbilled receivables | 1,081 | -1,407 | -488 | -363 | -91 |
| Due from related parties | 0 | -48 | 34 | -1,451 | |
| Inventory | -1,475 | 562 | -2,209 | -312 | -2,667 |
| Prepaid expenses and other current assets | 436 | -222 | 1,496 | -1,837 | -666 |
| Prepaid inventory | 0 | -693 | 412 | 281 | |
| Other long term assets | 240 | 325 | -220 | -632 | -1,201 |
| Other assets - related party | 260 | ||||
| Accounts payable | 2,427 | 382 | 533 | -1,570 | 1,436 |
| Deferred grant funding | 929 | -593 | -123 | -1,891 | 1,052 |
| Deferred revenue | -241 | 93 | -483 | 1,664 | 1,082 |
| Due to related parties | -11 | 0 | 61 | -1,981 | 1,845 |
| Accrued expenses and other current liabilities | 332 | -683 | -742 | -2,146 | 6,851 |
| Operating lease liabilities, net | -8 | -5 | 10 | ||
| Net cash used in operating activities | -27,948 | -38,767 | -41,809 | -72,339 | -47,182 |
| Purchases of property and equipment | -1,185 | -383 | -804 | -585 | -2,711 |
| Net cash used in investing activities | -1,185 | -383 | -804 | -585 | -2,711 |
| Proceeds from exercise of stock options | 156 | 171 | 174 | 7 | 1,497 |
| Proceeds from shares issued under ATM Sales Agreement, net of selling costs | 848 | ||||
| Proceeds from issuance of Class A common stock in connection with warrant exercises | 337 | ||||
| Net cash provided by financing activities | 27,502 | 1,019 | 174 | 7 | 176,767 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -1,631 | -38,131 | -42,439 | -72,917 | 126,874 |
| Proceeds from issuance of Series D convertible preferred stock | 30,468 | ||||
| Cash, cash equivalents and restricted cash, beginning of period | 37,673 | 75,804 | 118,243 | 191,160 | 64,286 |
| Stock issuance costs related to Series D convertible preferred stock | -7 | ||||
| Cash, cash equivalents and restricted cash, end of period | 36,042 | 37,673 | 75,804 | 118,243 | 191,160 |
| Repayment of notes payable | -178 | ||||
| Investment from 4Bionics, LLC | 3,516 | ||||
| Cash and cash equivalents | 35,085 | 37,645 | 75,183 | 117,472 | 188,498 |
| Net proceeds from equity infusion from the Business Combination | 141,471 | ||||
| Restricted cash | 957 | 28 | 621 | 771 | 2,662 |
| Cash received from exchange of research and development tax credits | 0 | 519 | 131 | 374 | |
| Unpaid purchase of property and equipment | 31 | 765 | 3 | ||
| Initial measurement of warrant liabilities | 2,858 | ||||
| Noncash acquisition of fixed assets | 217 | ||||
| Write-off of notes receivable | 90 | ||||
| Gross proceeds from issuance of common stock — Common Class A, At The Market Offering Program | 3,383 | ||||
| Proceeds from issuance of Class A common stock — Common Class A, February2025Offering | 5,183 | ||||
| Proceeds from issuance of Class A common stock in connection with warrant exercises — Common Class A, February2025Offering | 337 | ||||
| Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination | 3,000 | ||||
| Proceeds from issuance of Class A common stock — Common Class A, October2025Offering | 18,443 |